Please enable JavaScript to continue using this application.

Compare $AVTX vs $VSTM | Chartloom

Compare

$AVTX vs $VSTM

Avalo Therapeutics Inc · Verastem Inc

AVTX

Avalo Therapeutics Inc

VSTM

Verastem Inc

Compare $AVTX vs $VSTM

Comparing Avalo Therapeutics Inc and Verastem Inc

AVTXAvalo Therapeutics Inc

VSTMVerastem Inc

AVTXAvalo Therapeutics Inc

Market cap

$722M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-86.6%

YTD performance

-19.8%

52W performance

-4.0%

FCF yield

-9.5%

VSTMVerastem Inc

Market cap

$736M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

4.92x

Rev growth (TTM)

3995.7%

YTD performance

15.9%

52W performance

-6.3%

FCF yield

-23.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AVTX

VSTM

Detailed metrics comparison

AVTX

Avalo Therapeutics Inc

VSTM

Verastem Inc

Market Cap

AVTX$722M

VSTM$736M

Enterprise Value

AVTX$639M

VSTM$682M

Price

AVTX$13.65

VSTM$8.38

P/E Ratio

AVTXN/A

VSTMN/A

P/S Ratio

AVTX12,238.73x

VSTM8.41x

EV/Sales

AVTX10,825.47x

VSTM7.79x

EV/EBITDA

AVTX0.00x

VSTM0.00x

P/B Ratio

AVTX1.79x

VSTM14.07x

P/FCF Ratio

AVTXN/A

VSTMN/A

EV/FCF

AVTX-9.35x

VSTM-3.97x

PEG Ratio

AVTXN/A

VSTMN/A

Forward P/E (NTM)

AVTXN/A

VSTMN/A

Forward P/S (NTM)

AVTXN/A

VSTM4.92x

Revenue (TTM)

AVTX$59K

VSTM$88M

Revenue Growth (YoY)

AVTX-86.6%

VSTM3995.7%

Forward Rev Growth

AVTX1345.1%

VSTM61.6%

Gross Margin (TTM)

AVTX242.2%

VSTM87.6%

Operating Margin (TTM)

AVTX0.0%

VSTM0.0%

EBITDA Margin (TTM)

AVTX-154659.3%

VSTM-181.3%

Net Margin (TTM)

AVTX-170055.9%

VSTM-231.6%

FCF Margin (TTM)

AVTX-115745.8%

VSTM-196.3%

Net Income (TTM)

AVTX$-100M

VSTM$-203M

FCF (TTM)

AVTX$-68M

VSTM$-172M

EPS (TTM)

AVTX-$2.30

VSTM-$2.02

ROE (TTM)

AVTX-5803.0%

VSTM-16540.0%

ROA (TTM)

AVTX-4822.0%

VSTM-9454.0%

ROIC (TTM)

AVTX-5729.0%

VSTM-7104.0%

Cash

AVTX$85M

VSTM$136M

Debt

AVTX$2M

VSTM$82M

Net Cash/Debt

AVTX$83M

VSTM$55M

Current Ratio (TTM)

AVTX19.31x

VSTM2.25x

Quick Ratio (TTM)

AVTX18.95x

VSTM2.12x

Debt/Equity (TTM)

AVTX0.00x

VSTM1.63x

Debt/Assets (TTM)

AVTX0.0%

VSTM0.0%

Interest Coverage (TTM)

AVTXN/A

VSTMN/A

Net Debt/EBITDA (TTM)

AVTX0.00x

VSTM0.00x

Beta

AVTX0.62

VSTM0.58

52W Performance

AVTX-4.0%

VSTM-6.3%

YTD Performance

AVTX-19.8%

VSTM15.9%

% from 52W High

AVTX-43.8%

VSTM-22.6%

% from 52W Low

AVTX9.1%

VSTM144.3%

Asset Turnover (TTM)

AVTX0.00x

VSTM0.41x

FCF Yield (TTM)

AVTX-9.5%

VSTM-23.3%

Earnings Yield (TTM)

AVTX-13.9%

VSTM-27.5%

Dividend Yield (TTM)

AVTXN/A

VSTMN/A

Rule of 40

AVTX-115,832.4

VSTM3,799.4

EV/GP/RG

AVTX1.31

VSTM0.13

Ticker research

View AVTX research View VSTM research

Metric	AVTX Avalo Therapeutics Inc	VSTM Verastem Inc
Market & Valuation
Market Cap	$722M	$736M
Enterprise Value	$639M	$682M
Price	$13.65	$8.38
P/E Ratio	N/A	N/A
P/S Ratio	12,238.73x	8.41x
EV/Sales	10,825.47x	7.79x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.79x	14.07x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.35x	-3.97x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	4.92x
Revenue & Growth
Revenue (TTM)	$59K	$88M
Revenue Growth (YoY)	-86.6%	3995.7%
Forward Rev Growth	1345.1%	61.6%
Profitability
Gross Margin (TTM)	242.2%	87.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-154659.3%	-181.3%
Net Margin (TTM)	-170055.9%	-231.6%
FCF Margin (TTM)	-115745.8%	-196.3%
Net Income (TTM)	$-100M	$-203M
FCF (TTM)	$-68M	$-172M
EPS (TTM)	-$2.30	-$2.02
ROE (TTM)	-5803.0%	-16540.0%
ROA (TTM)	-4822.0%	-9454.0%
ROIC (TTM)	-5729.0%	-7104.0%
Financial Health
Cash	$85M	$136M
Debt	$2M	$82M
Net Cash/Debt	$83M	$55M
Current Ratio (TTM)	19.31x	2.25x
Quick Ratio (TTM)	18.95x	2.12x
Debt/Equity (TTM)	0.00x	1.63x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	0.58
52W Performance	-4.0%	-6.3%
YTD Performance	-19.8%	15.9%
% from 52W High	-43.8%	-22.6%
% from 52W Low	9.1%	144.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.41x
FCF Yield (TTM)	-9.5%	-23.3%
Earnings Yield (TTM)	-13.9%	-27.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-115,832.4	3,799.4
EV/GP/RG	1.31	0.13
Ticker research	View AVTX research	View VSTM research

Valuation

P/S Ratio

VSTM

8.41x

AVTX

12,238.73x

EV/FCF

AVTX

-9.35x

VSTM

-3.97x

Growth & revenue

Revenue Growth TTM

VSTM

3995.7%

AVTX

-86.6%

Forward Revenue Growth

AVTX

1345.1%

VSTM

61.6%

Profitability & performance

Gross Margin

AVTX

242.2%

VSTM

87.6%

ROE

AVTX

-5803.0%

VSTM

-16540.0%

FCF Yield %

AVTX

-9.5%

VSTM

-23.3%

52-Week Performance

AVTX

-4.0%

VSTM

-6.3%

Detailed metrics comparison

AVTX

Avalo Therapeutics Inc

VSTM

Verastem Inc

Market Cap

AVTX$722M

VSTM$736M

Enterprise Value

AVTX$639M

VSTM$682M

Price

AVTX$13.65

VSTM$8.38

P/E Ratio

AVTXN/A

VSTMN/A

P/S Ratio

AVTX12,238.73x

VSTM8.41x

EV/Sales

AVTX10,825.47x

VSTM7.79x

EV/EBITDA

AVTX0.00x

VSTM0.00x

P/B Ratio

AVTX1.79x

VSTM14.07x

P/FCF Ratio

AVTXN/A

VSTMN/A

EV/FCF

AVTX-9.35x

VSTM-3.97x

PEG Ratio

AVTXN/A

VSTMN/A

Forward P/E (NTM)

AVTXN/A

VSTMN/A

Forward P/S (NTM)

AVTXN/A

VSTM4.92x

Revenue (TTM)

AVTX$59K

VSTM$88M

Revenue Growth (YoY)

AVTX-86.6%

VSTM3995.7%

Forward Rev Growth

AVTX1345.1%

VSTM61.6%

Gross Margin (TTM)

AVTX242.2%

VSTM87.6%

Operating Margin (TTM)

AVTX0.0%

VSTM0.0%

EBITDA Margin (TTM)

AVTX-154659.3%

VSTM-181.3%

Net Margin (TTM)

AVTX-170055.9%

VSTM-231.6%

FCF Margin (TTM)

AVTX-115745.8%

VSTM-196.3%

Net Income (TTM)

AVTX$-100M

VSTM$-203M

FCF (TTM)

AVTX$-68M

VSTM$-172M

EPS (TTM)

AVTX-$2.30

VSTM-$2.02

ROE (TTM)

AVTX-5803.0%

VSTM-16540.0%

ROA (TTM)

AVTX-4822.0%

VSTM-9454.0%

ROIC (TTM)

AVTX-5729.0%

VSTM-7104.0%

Cash

AVTX$85M

VSTM$136M

Debt

AVTX$2M

VSTM$82M

Net Cash/Debt

AVTX$83M

VSTM$55M

Current Ratio (TTM)

AVTX19.31x

VSTM2.25x

Quick Ratio (TTM)

AVTX18.95x

VSTM2.12x

Debt/Equity (TTM)

AVTX0.00x

VSTM1.63x

Debt/Assets (TTM)

AVTX0.0%

VSTM0.0%

Interest Coverage (TTM)

AVTXN/A

VSTMN/A

Net Debt/EBITDA (TTM)

AVTX0.00x

VSTM0.00x

Beta

AVTX0.62

VSTM0.58

52W Performance

AVTX-4.0%

VSTM-6.3%

YTD Performance

AVTX-19.8%

VSTM15.9%

% from 52W High

AVTX-43.8%

VSTM-22.6%

% from 52W Low

AVTX9.1%

VSTM144.3%

Asset Turnover (TTM)

AVTX0.00x

VSTM0.41x

FCF Yield (TTM)

AVTX-9.5%

VSTM-23.3%

Earnings Yield (TTM)

AVTX-13.9%

VSTM-27.5%

Dividend Yield (TTM)

AVTXN/A

VSTMN/A

Rule of 40

AVTX-115,832.4

VSTM3,799.4

EV/GP/RG

AVTX1.31

VSTM0.13

Ticker research

View AVTX research View VSTM research

Metric	AVTX Avalo Therapeutics Inc	VSTM Verastem Inc
Market & Valuation
Market Cap	$722M	$736M
Enterprise Value	$639M	$682M
Price	$13.65	$8.38
P/E Ratio	N/A	N/A
P/S Ratio	12,238.73x	8.41x
EV/Sales	10,825.47x	7.79x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.79x	14.07x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.35x	-3.97x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	4.92x
Revenue & Growth
Revenue (TTM)	$59K	$88M
Revenue Growth (YoY)	-86.6%	3995.7%
Forward Rev Growth	1345.1%	61.6%
Profitability
Gross Margin (TTM)	242.2%	87.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-154659.3%	-181.3%
Net Margin (TTM)	-170055.9%	-231.6%
FCF Margin (TTM)	-115745.8%	-196.3%
Net Income (TTM)	$-100M	$-203M
FCF (TTM)	$-68M	$-172M
EPS (TTM)	-$2.30	-$2.02
ROE (TTM)	-5803.0%	-16540.0%
ROA (TTM)	-4822.0%	-9454.0%
ROIC (TTM)	-5729.0%	-7104.0%
Financial Health
Cash	$85M	$136M
Debt	$2M	$82M
Net Cash/Debt	$83M	$55M
Current Ratio (TTM)	19.31x	2.25x
Quick Ratio (TTM)	18.95x	2.12x
Debt/Equity (TTM)	0.00x	1.63x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	0.58
52W Performance	-4.0%	-6.3%
YTD Performance	-19.8%	15.9%
% from 52W High	-43.8%	-22.6%
% from 52W Low	9.1%	144.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.41x
FCF Yield (TTM)	-9.5%	-23.3%
Earnings Yield (TTM)	-13.9%	-27.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-115,832.4	3,799.4
EV/GP/RG	1.31	0.13
Ticker research	View AVTX research	View VSTM research